3 ms·
Helpful article. The headlines and editorial coverage of this made it look fantastic, except for any of the concrete information in the story I read, which made
by pessimizer 4y ago
Helpful article. The headlines and editorial coverage of this made it look fantastic, except for any of the concrete information in the story I read, which made it look most likely completely worthless.
https://www.theguardian.com/society/2022/sep/28/alzheimers-disease-progression-slowed-by-new-drug-lecanemab https://www.theguardian.com/society/2022/sep/28/alzheimers-d...
> Success of experimental Alzheimer’s drug hailed as ‘historic moment’: Study shows cognition in early-stage patients on lecanemab declines by 27% less than those on placebo
Wow, something's happening!
> The cognition of Alzheimer’s patients given the drug, developed by Eisai and Biogen, declined by 27% less than those on a placebo treatment after 18 months. This is a modest change in clinical outcome but it is the first time any drug has been clearly shown to alter the disease’s trajectory.
We've gone from "historic" to "modest" in two paragraphs.
> On a 14-point scale used to assess Alzheimer’s progression, patients on the drug scored 0.45 higher than those on the placebo treatment, with an Alzheimer’s patient being expected to decline by about 1 point a year.
That is very modest. And it's a questionnaire, not memory testing?
> Howard said: “The accepted minimum worthwhile difference ranges from 0.5 to 1.0 points, [meaning] that there are going to be some very difficult conversations and decisions in the next weeks and months.”
So it's not even clinically significant? They have a metric that they decided to call the "accepted minimum worthwhile difference," and this is less than that. Doesn't that mean it's not worthwhile? I'm guessing based on the name.
Is this just the first of a series of press releases to start building up public sentiment that can be eventually used to avoid the controversy generated when the FDA approved the last Alzheimer's drug that definitely didn't work?
- mmastrac 4y agoI don't necessarily disagree with your premise, but something _can_ be both historic and modest. The first, tiny steps can show that there's something we can do about it and that's historic. Whether these benefits actually exist... well I'm on the same page as you with skepticism.
- pessimizer 4y ago> something _can_ be both historic and modest. Totally agreed. But can something be both "historic" and not even "minim[ally] worthwhile"?
- aidenn0 4y agoYes, something can be historic from a reasearch and knowledge point of view while not being worthwhile clinically.
- pessimizer 4y agoOr a minimal or nonexistent effect could be used to justify a continued investment in a bad direction.
- andrewflnr 4y agoYes, those are both possibilities. We don't know yet. What are you expecting, that we'll figure it out by pure reason here in HN comments? Wait for the rest of the evidence.
- bigDinosaur 4y agoAre there good examples of clinically worthless research and medicines later leading to genuinely worthwhile cures/treatments etc? I can't think of any but I am curious what examples you have in mind.
- aidenn0 4y agoThe first recipient of a human heart transplant died 18 days later. Now the average life after one is 15 years.
- rowanG077 4y agoBasically every piece of medical knowledge starts out as clinically worthless and over time grows into it. mRNA was clinically worthless until COVID. Radiation therapy did more harm then good when invented but is now a staple. CRISPR is still clinically worthless afaik.
- adamredwoods 4y agodoh! /removed obvious link
- deleted 4y ago[deleted]
- qqqwerty 4y agoIt sounds like the question they still need to answer is if this effect continues indefinitely, or if it is a one time effect. Across a 10 year disease progression this could slow it down by 2.5 years. I might make that trade off, at least in the early stages of the disease. Not sure I would want to slow things down in the later stages though. At that point just get it over with. It is also not clear from the press release what the response distribution looks like. If some people respond really well and others do not (but it averages out to 27%), maybe Alzheimers treatment starts to look a bit more like cancer. Where you try a few things and hope something sticks. My hunch is that is probably where we are headed, but I am not an expert in this stuff.
- pessimizer 4y ago> Across a 10 year disease progression this could slow it down by 2.5 years. I might make that trade off, at least in the early stages of the disease. Not sure I would want to slow things down in the later stages though. At that point just get it over with. Especially since it seems like there might be some pretty brutal side effects.
- ekianjo 4y agoIf you read Biogen you already know thete is nothing but fluff at this stage.